MedTrace Logo

Role NLRP3 Inflammasome in Weight Loss Following Sleeve Gastrectomy in Morbidly Obese Patients

NCT04814147 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2023-08-28

No results posted yet for this study

Summary

Epidemiological studies show a very rapid increase in the epidemic of obesity in the Caribbean population. 6 out of 10 adults are overweight and 1 out of 4 is obese. Most are women.

Consequences : harm to health and possible reduction in life expectancy due to the association with many cardiovascular comorbidities.

Adverse effects of obesity on the cardiovascular and endocrine systems are attributed a chronic low-grade inflammatory state in obese patients. Visceral adipose tissue is largely responsible for the inflammatory syndrome. Obesity can also induce the formation of multi-protein platforms called inflammasomes also activated by mitochondrial production.

Morbid obesity treatment with sleeve gastrectomy is an effective long term therapeutic for weight loss but also beneficial in terms of insulin resistance and cardiovascular complications.

Some patients nevertheless remain resistant to the beneficial cardio-metabolic effects of bariatric surgery.

However, the mechanisms that regulate the extent of weight loss and its stabilization after bariatric surgery are still poorly understood.

Our study aims to describe the evolution of postoperative weight loss and the place of preoperative inflammation in its amplitude.

The hypothesis is that the level of inflammation in visceral fat before surgery determines the extent of postoperative weight loss in obese women who have undergone sleeve gastrectomy.

Conditions

  • Obesity Morbid
  • Obesity-Associated Insulin Resistance

Interventions

PROCEDURE

Sleeve gastrectomy

Measure of NLRP3 inflammasome preoperative activation level by the expression of NLRP3, IL-1β, IL18 and caspase-1 mRNAs in subcutaneous and visceral adipose tissue. of the epiploon;

Sponsors & Collaborators

  • University Hospital Center of Martinique

    lead OTHER

Principal Investigators

  • Rémi NEVIERE, MD, PhD · CHU de Martinique

  • Emmanuel RIVKINE · CHU de Martinique

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-13
Primary Completion
2024-06-13
Completion
2025-06-12

Countries

  • Martinique

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04814147 on ClinicalTrials.gov